|
Brain Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Induction of protein inhibitor of neuronal nitric oxide synthase/cytoplasmic dynein light chain following cerebral ischemia.
|
9522364 |
1998 |
|
Cerebral Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Induction of protein inhibitor of neuronal nitric oxide synthase/cytoplasmic dynein light chain following cerebral ischemia.
|
9522364 |
1998 |
|
Heart failure
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
Previously we have shown increased protein expression of PIN (a protein inhibitor of nNOS: neuronal nitric oxide synthase, known to dissociate nNOS dimers into monomers) with concomitantly reduced levels of catalytically active dimers of nNOS in the PVN of rats with heart failure.
|
31654775 |
2020 |
|
Congestive heart failure
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
Previously we have shown increased protein expression of PIN (a protein inhibitor of nNOS: neuronal nitric oxide synthase, known to dissociate nNOS dimers into monomers) with concomitantly reduced levels of catalytically active dimers of nNOS in the PVN of rats with heart failure.
|
31654775 |
2020 |
|
Heart failure
|
0.210 |
Biomarker
|
disease |
RGD |
Angiotensin II-mediated posttranslational modification of nNOS in the PVN of rats with CHF: role for PIN.
|
23832698 |
2013 |
|
Congestive heart failure
|
0.210 |
Biomarker
|
disease |
RGD |
There is an ANG II-driven, PIN-mediated decrease in the dimeric catalytically active nNOS in the PVN, due to ubiquitin-dependent proteolytic degradation in CHF.
|
23832698 |
2013 |
|
Erectile dysfunction
|
0.210 |
Therapeutic
|
disease |
RGD |
Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat.
|
17433082 |
2007 |
|
Erectile dysfunction
|
0.210 |
Biomarker
|
disease |
BEFREE |
Gene therapy to the penile corpora cavernosa of cDNAs expressing PnNOS or eNOS, or counteracting PIN, has been effective in ameliorating ED in the aging rat model that exhibits both neurogenic ED and CVOD. cDNA constructs for other genes involved in the control of penile erection have also been successfully tested.
|
15582286 |
2005 |
|
Hypertensive disease
|
0.200 |
Therapeutic
|
group |
RGD |
RNA silencing targeting PIN (protein inhibitor of neuronal nitric oxide synthase) attenuates the development of hypertension in young spontaneously hypertensive rats.
|
24035314 |
2014 |
|
Cardiac Arrest
|
0.200 |
Biomarker
|
disease |
RGD |
Induction of protein inhibitor of neuronal nitric oxide synthase/cytoplasmic dynein light chain following cerebral ischemia.
|
9522364 |
1998 |
|
Cardiopulmonary Arrest
|
0.200 |
Biomarker
|
phenotype |
RGD |
Induction of protein inhibitor of neuronal nitric oxide synthase/cytoplasmic dynein light chain following cerebral ischemia.
|
9522364 |
1998 |
|
Infarction, Middle Cerebral Artery
|
0.200 |
Biomarker
|
disease |
RGD |
Induction of protein inhibitor of neuronal nitric oxide synthase/cytoplasmic dynein light chain following cerebral ischemia.
|
9522364 |
1998 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the most frequent benign mimickers that prevent a definitive diagnosis of cancer in needle biopsies are the small size of the atypical foci, PIN and partial atrophy, in TURPs, they are adenosis and cautery artifact.
|
27299192 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Utilizing a novel approach for deconvolution, we analyze the transcriptomes of nearly 6750 tissue regions and extract distinct expression profiles for the different tissue components, such as stroma, normal and PIN glands, immune cells and cancer.
|
29925878 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer.<b>Experimental Design:</b> By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, <i>in vitro</i> macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer.<b>Results:</b> Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages.
|
30012567 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer.<b>Experimental Design:</b> By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, <i>in vitro</i> macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer.<b>Results:</b> Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages.
|
30012567 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Role of Tumor Suppressor DLC-1: Far From Clear.
|
27604574 |
2017 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Various important genes encoding tumor suppressors including P16, RASSF1A, DLC-1, RUNX3 and SOCS-1 are targets of epigenetic dysregulation during the development of HCC.
|
27271356 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 has been identified as a candidate tumor suppressor.
|
27366946 |
2016 |
|
Reticulocyte count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prostate-specific G-protein coupled receptor (PSGR, or OR51E2) is an olfactory receptor family member with highly specific expression in human prostate epithelium that is highly overexpressed in PIN and prostate cancer.
|
27280498 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant DLC-1 expression may play an important role in cancer genesis and metastasis.
|
26514520 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DLC-1 expression was not found to be associated with tumor differentiation status.
|
26514520 |
2015 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No association was found for correlation of PCA3 score change with age >65 years (p=0.975), family history of prostate cancer (p=0.796), positive DRE (p=0.179), use of 5-alpha-reductase inhibitors (p=0.793) and BPH/prostatitis/HG-PIN/ASAP diagnosis (p=0.428).
|
25862908 |
2015 |